FDMT · 4D Molecular Therapeutics, Inc.
$9.61
-0.24 (-2.44%)
At close · Jul 29
Market Cap
$681.74M
Shares
69.21M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-20 | 2026-07-18 | |
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-29 | 2026-06-24 | |
| 8-K | 2026-06-22 | 2026-06-17 | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| DEF 14A | 2026-04-28 | 2026-06-17 | |
| Investor Event Transcript | 2026-03-31 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-03-30 | 2026-03-25 | |
| 8-K | 2026-03-18 | — | |
| 10-K | 2026-03-18 | 2025-12-31 | |
| 8-K | 2026-01-26 | 2026-01-22 | |
| 8-K | 2026-01-07 | 2025-12-31 | |
| Investor Event Transcript | 2025-12-31 | — | |
| 8-K | 2025-12-10 | — | |
| 8-K | 2025-11-17 | — | |
| 10-Q | 2025-11-10 | 2025-09-30 | |
| 8-K | 2025-11-10 | — | |
| 8-K | 2025-11-07 | 2025-11-06 | |
| 8-K | 2025-11-06 | — | |
| 8-K | 2025-10-31 | — | |
| 8-K | 2025-10-02 | 2025-09-30 | |
| 8-K | 2025-08-11 | — | |
| 10-Q | 2025-08-11 | 2025-06-30 | |
| 8-K | 2025-07-02 | 2025-06-27 | |
| 8-K | 2025-06-20 | 2025-06-17 | |
| 8-K | 2025-05-08 | — | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| DEF 14A | 2025-04-29 | 2025-06-17 | |
| 8-K | 2025-02-28 | — | |
| 10-K | 2025-02-28 | 2024-12-31 | |
| 8-K | 2025-02-10 | 2025-02-08 | |
| 8-K | 2025-01-10 | — | |
| 8-K | 2024-12-11 | 2024-12-06 | |
| 8-K | 2024-11-13 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-09-18 | — | |
| 8-K | 2024-08-08 | — | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-07-23 | — | |
| 8-K | 2024-07-17 | — | |
| 8-K | 2024-06-07 | — | |
| 8-K | 2024-05-24 | 2024-05-21 | |
| 8-K | 2024-05-09 | — | |
| 10-Q | 2024-05-09 | 2024-03-31 | |
| DEF 14A | 2024-04-10 | 2024-05-21 | |
| 10-K | 2024-02-29 | 2023-12-31 | |
| 8-K | 2024-02-29 | — |
Showing 1–50 of 97 filings
Key facts
CIK
1650648
CUSIP
35104E100
13F (30d)
22 filings
22 filers
Visit website
Investor relations